Clinical Research Directory
Browse clinical research sites, groups, and studies.
Low Dose Oral Minoxdil in Androgenic Alopecia
Sponsor: Jinnah Postgraduate Medical Centre
Summary
In order to successfully treat androgenetic alopecia (AGA), this study compares the efficacy of low-dose oral minoxidil dosages of 0.25 mg and 1 mg. It addresses a critical gap in current research, as few studies have examined the relationship between low dosage and outcomes like hair diameter, density, patient satisfaction, and adverse effects, including hypertrichosis. Previous research suggests that low dose of oral minoxidil is a safe and well-tolerated option for hair loss, but the optimal dose for maximizing benefits while minimizing side effects remains unclear. This study aims to determine which dose offers the best balance of efficacy and safety for AGA patients.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2025-06-15
Completion Date
2025-10-20
Last Updated
2025-06-12
Healthy Volunteers
No
Conditions
Interventions
2.5% Oral minoxidil
AGA patients will be randomly allocated in both groups using the envelopes method to reduce the biasness. For 3-months, patients in Group-A will get 2.5mg of minoxidil once daily, while those in Group-B will receive 1mg of minoxidil once daily orally. After starting therapy, patients will be asked to come back for evaluations 3 months later. Safety, satisfaction, and the effects of the treatment will be reported. Final outcomes will be evaluated at 3 months post treatment.
1% Oral Minoxidil
Group-B will receive 1mg of minoxidil once daily orally
Locations (1)
Jinnah PMC
Karachi, Sindh, Pakistan